Quick View: Despite Late Entry, Teva And Alvotech's Humira Biosimilar Is Set To Dominate
Pharmaceuticals / United States / Tue 27 Feb, 2024
The Latest: On February 23 2024, the US FDA approved Simlandi (adalimumab-ryvk), a biosimilar to AbbVie’s blockbuster drug Humira (adalimumab). The approval marks a significant milestone for Teva and its partner, Alvotech, as Simlandi becomes the first high-concentration, citrate-free biosimilar to Humira with an interchangeability designation